hero image

Biogen Idec Names Adam M. Koppel as SVP and Chief Strategy Officer

April 10, 2014 Corporate

– Will Lead Corporate Strategy and Portfolio Management in Newly Created Role –

 

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) today announced the appointment of Adam M. Koppel, M.D., Ph.D., as senior vice president and chief strategy officer, effective May 15, 2014.

Dr. Koppel will be responsible for leading corporate strategy and portfolio management, as well as ensuring that disease strategies clearly align with the corporate strategy. He will report to George Scangos, Ph.D., chief executive officer, and will be a member of the Biogen Idec management team.

“With his experience as a physician, scientist and executive, Adam will be invaluable to Biogen Idec as we grow in size and complexity, bringing a unique set of capabilities to bolster our position at the intersection of medicine, science and economics,” said Dr. Scangos. “Adam is a respected biotechnology investor and industry leader, and we are thrilled to have his insight and vision to help guide our company and management team.”

Dr. Koppel will join Biogen Idec from Brookside Capital, the public equity affiliate of Bain Capital, where he joined in 2003, serving as a managing director since 2009. Prior to Brookside Capital, he was an associate principal of the McKinsey Healthcare Practice. He holds Bachelor and Master of Arts degrees in History and Science from Harvard College and earned an M.D. and Ph.D. in Molecular Neurobiology from the University of Pennsylvania. He also received an M.B.A. from the University of Pennsylvania’s Wharton School.

“Adam has been a great partner, and we wish him all the best as he leaves public equity investing to pursue his passion for biotechnology at Biogen Idec,” said Ted Pappendick, a managing director at Brookside Capital.

About Biogen Idec

Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies. For product labeling, press releases and additional information about the Company, please visit www.biogenidec.com.

Contact:

 

MEDIA CONTACTS:
Biogen Idec
Jason Glashow, +1-781-464-3260
public.affairs@biogenidec.com
or
Biogen Idec
Kate Niazi-Sai, +1-781-464-3260
public.affairs@biogenidec.com
or
INVESTOR CONTACTS:
Biogen Idec
Benjamin Strain, +1-781-464-2442
IR@biogenidec.com

 

 

thumb
January 26, 2023
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the European Medicines

thumb
January 18, 2023
BIOGEN TO REPORT FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS FEBRUARY 15, 2023

Cambridge, Mass.— Biogen Inc . (Nasdaq:BIIB) today announced it will report fourth quarter and full year 2022 financial results Wednesday, February 15, 2023, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at